Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Capitol Capsule: Stem cell researchers breathe sigh of relief on vacated injunction

This article was originally published in Scrip

Executive Summary

Researchers last week cheered a 29 April ruling by a US appeals court that vacated an injunction imposed last August by a lower court on federal funding for research involving human embryonic stem cells (hESCs) – with the latest decision giving the Obama administration a big win in the case. The ruling also bodes well for companies involved in hESC research, although the 29 April decision has no impact on the clinical trials underway by the two US firms already given the US FDA's blessing to move forward.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC012762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel